Back to results
US 2023/0271925 A1Published application
Novel tnf activity inhibitor compound, and pharmaceutically acceptable salt thereof
AssigneeILAb
InventorKyung Yeon Park
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel TNF activity inhibitor compound and a pharmaceutically acceptable salt thereof, a method for prevention, alleviation or treatment comprising administering the compound of the present invention, a method for preparing the compound of the present invention, and a pharmaceutical composition comprising the compound.
Claims17
The compound of Formula I below or a pharmaceutically acceptable salt thereof:
- wherein,
- X is —C(R3)2—, —N(R3)—, —O— or —S—,
- Y is —ORa, —SRa, —C(O)Ra, —C(O)ORa, —C(O)N(Ra)(Rb), —N(Ra)(Rb), —N(Ra)C(O)Rb, —N(Ra)C(O)ORb, or —N(Ra)S(O)ORb,
- A is C3-C8 cycloalkyl;
- 4- to 10-membered heterocycloalkyl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S;
- C6-C10 aryl;
- or 5- to 10-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S,
- R1, R2 and R3 may be the same or different and are each independently H, halo, cyano, —ORc, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —SRc, —C(O)Rc, —C(O)ORc, —C(O)N(Rc)(Rd), —N(Rc)(Rd), —N(Rc)C(O)Rd, —N(Rc)C(O)ORd, or —N(Rc)S(O)ORd,
- Ra, Rb, Rc and Rd may be the same or different and are each independently H or C1-C6 alkyl, and
- m and n are each independently an integer from 0 to 4.
7 more elements
A compound of Formula III below or a pharmaceutically acceptable salt thereof:
- M1-L-M2 [Formula III]
- wherein,
- M1 and M2 may be the same or different, and are each independently a monomer radical of Formula Ia, and
- L is a linking group covalently bonding M1 and M2, and is selected from the following Formulas IVa to IVc,
- (wherein,
- X is —C(R3)2—, —N(R3)—, —O— or —S—,
- Y is —ORa, —SRa, —C(O)Ra, —C(O)ORa, —C(O)N(Ra)(Rb), —N(Ra)(Rb), —N(Ra)C(O)Rb, —N(Ra)C(O)ORb, or —N(Ra)S(O)ORb,
- A is C3-C8 cycloalkyl;
- 4- to 10-membered heterocycloalkyl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S;
- C6-C10 aryl;
- or 5- to 10-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S,
- R1, R2 and R3 may be the same or different and each independently H, halo, cyano, —ORc, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —SRc, —C(O)Rc, —C(O)ORc, —C(O)N(Rc)(Rd), —N(Rc)(Rd), —N(Rc)C(O)Rd, —N(Rc)C(O)ORd, or —N(Rc)S(O)ORd,
- Ra, Rb, Rc and Rd may be the same or different and are each independently H or C1-C6 alkyl,
- m and n are each independently an integer of 0 to 4,
- the monomer unit M1 or M2 is bonded to the linking group L through a bonding site * located in either Y or R2, and
- when Y or R2 has the above bonding site *, Y or R2 contains N, O or S atoms, and at the bonding site *, —C(O)—, —NH—, —N(C1-C6 alkyl)-, —O— or —S— radical is located),
- (wherein,
- * represents a bonding site between the monomer unit M1 or M2 and the linking group L,
- R or R′ is each independently C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene;
- Z is a single bond;
- —O—;
- —S—;
- —NH—;
- —N(C1-C6 alkyl)-;
- C3-C8 cycloalkylene;
- 4- to 10-membered heterocycloalkyl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S;
- C6-C10 aryl;
- or 5- to 10-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S;
- p is an integer from 1 to 5, and
- q1 and q2 are each independently an integer from 0 to 5, but q1 and q2 are not 0 at the same time).
27 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.